NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
At risk: Primary completion moved at least 1 year 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 22 versions: 22 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Oct 20, 2026 to Aug 11, 2028
- Study completion pushed from Feb 15, 2027 to Nov 11, 2028
- Study sites revised (61)
- Notable Eligibility criteria expanded, about 21 words
- Trial sites expanded: 36 → 61 locations
- Secondary endpoints: details revised at 5 of 18 entries
- Publications: details revised at 1 of 1 entry
- Minor Trial sites expanded: 33 → 36 locationsv20
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 12 words
- Enrollment target: 540 to 590
- Secondary endpoints: 13 to 18
- Notable Primary completion pushed from Mar 17, 2026 to Oct 20, 2026
- Study sites: 32 to 33
Show 16 earlier versionsHide 16 earlier versions
- Minor Study sites: 27 to 32v17
- Minor Study sites: 24 to 27v16
- Notable Eligibility criteria expanded, about 15 words
- Enrollment target: 470 to 540
- Study completion date: Jul 11, 2027 to Feb 15, 2027
- Site details revised at 1 of 24 sites
- Minor Site details revised at 1 of 24 sitesv14
- Minor Site details revised at 3 of 24 sitesv13
- Minor Study sites: 20 to 24v12
- Minor Study sites: 14 to 20v11
- Notable Eligibility criteria expanded, about 26 words
- Enrollment target: 430 to 470
- Minor Study sites: 5 to 14v9
- Minor Study sites: 6 to 5v8
- Minor Site details revised at 1 of 6 sitesv7
- Notable Eligibility criteria expanded, about 1 wordv6
- Minor Site details revised at 1 of 6 sitesv5
- Minor Site details revised at 1 of 6 sitesv4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 2023 to Aug 18, 2023
- Site details revised at 6 of 6 sites
- Minor Study sites: 0 to 6v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Dose-limiting Toxicities Following Treatment With DS-3939a
Timeframe: Approximately 3 months after first dosing
Overall Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events Following Treatment With DS-3939a
Timeframe: Up to approximately 31 months
Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 2)
Timeframe: Up to approximately 31 months
PSA50 Response Rate Following Treatment with DS-3939a (Part 2; CRPC only)
Timeframe: Up to approximately 31 months
Secondary (18)
Number of Participants with Objective Response Rate Following Treatment With DS-3939a (Part 1)
Disease Control Rate Following Treatment With DS-3939a
Duration of Response Following Treatment With DS-3939a
Time to Response Following Treatment With DS-3939a
Progression Free Survival Following Treatment With DS-3939a
Show 13 moreShow less
Overall Survival Following Treatment With DS-3939a
TA-MUC1 Expression by Immunohistochemistry Following Treatment With DS-3939a
Area Under the Plasma Concentration Curve (AUC) Following Treatment With DS-3939a
Maximum Plasma Concentration (Cmax) Following Treatment With DS-3939a
Time to Maximum Plasma Concentration (Tmax) Following Treatment With DS-3939a
Minimum Observed Concentration (Ctrough) Following Treatment With DS-3939a
Terminal Half-Life (T1/2) Following Treatment With DS-3939a
Number of Participants With Treatment-emergent Anti-drug Antibodies Following Treatment With DS-3939a
PSA50 Response Rate Following Treatment with DS-3939a (Part 1; CRPC only)
PSA30 and PSA90 Response Rate Following Treatment with DS-3939a (CRPC only)
Time to PSA Progression Following Treatment with DS-3939a (CRPC only)
Radiographic Progression-free Survival (PCWG 3) Following Treatment with DS-3939a (CRPC only)
Overall Survival Following Treatment with DS-3939a (CRPC only)
Arms and interventions
Dose Escalation (Part 1)Experimental
Participants with locally advanced, metastatic, or unresectable tumors who will receive an intravenous (IV) infusion of DS-3939a starting at 1 mg/kg.
Dose Expansion (Part 2)Experimental
Multiple expansion cohorts targeting various advanced solid tumors.
Drugs: DS-3939a
Sites
61 sites in 8 countries
United States 14, China 13, Japan 10, France 8, Spain 7, South Korea 6, Canada 2, Belgium 1